For Hepatocellular Carcinoma, Axitinib May Improve Survival, Time to Progression

Share this content:
Axitinib resulted in longer progression-free survival and time to tumor progression in patients with advanced hepatocellular carcinoma.
Axitinib resulted in longer progression-free survival and time to tumor progression in patients with advanced hepatocellular carcinoma.

Axitinib plus best supportive care resulted in significantly longer progression-free survival and time to tumor progression and higher clinical benefit rate than placebo plus best supportive care in patients with advanced hepatocellular carcinoma (HCC), a new study published online ahead of print in the journal Annals of Oncology has shown.1

For the phase 2 study, researchers sought to assess the efficacy and safety of axitinib, a potent and selective vascular endothelial growth factor receptors 1-3 inhibitor, plus best supportive care in patients with locally advanced or metastatic HCC.

Researchers enrolled patients with HCC and Child-Pugh Class A who progressed on or were intolerant to 1 prior antiangiogenic therapy and randomly assigned them 2:1 to receive axitinib twice daily combined with best supportive care or placebo plus best supportive care.

Results showed no significant difference in overall survival, the primary endpoint, between axitinib and placebo; however, improvements favoring axitinib plus best supportive care were observed in progression-free survival, time to tumor progression, and clinical benefit rate.

RELATED: Sorafenib Not Effective After Resection, Ablation for Hepatocellular Carcinoma

Researchers found that there was no significant difference in overall response rate between the 2 treatment arms and patient-reported outcomes favored placebo plus best supportive care.

In regard to safety, the most common adverse events in the axitinib group were diarrhea, hypertension, and decreased appetite.

Reference

  1. Kang Y-K, Yau T, Park J-W, et al. Randomised phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma [published online ahead of print September 18, 2015]. Ann Oncol. doi: 10.1093/annonc/mdv388.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters